CTIS2024-512502-26-00进行中（未招募）1 期
A Randomized Phase II Trial assessing Trimodality Therapy With or Without Adjuvant Durvalumab (MEDI4736) to Treat Patients with Muscle-Invasive Bladder Cancer - BL.13
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 131
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histologic diagnosis of urothelial carcinoma of the bladder. Patients with mixed histology (including small cell) and urothelial carcinoma are eligible. Patients with pure small cell carcinoma will be excluded, All patients must have a tumour block from their primary tumour available and consent to release for correlative analyses, Patients have completed prior trimodality therapy (TMT) consisting of surgery, chemotherapy and radiation therapy treatment prior to enrollment on the BL.13 study Patients should begin protocol treatment within 42 days after completion of TMT, Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires in either english, french or spanish, Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements, Patients must be accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centre, In accordance with CCTG policy, protocol treatment is to begin within 2 working days of patient enrollment, Women/men of childbearing potential must have agreed to use a highly effective contraceptive method during and for 3 months following treatment. Women of childbearing potential will have a pregnancy test to determine eligibility as part of the Pre-Study Evaluation, Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial, Stage T2-T4a N0M0 at time of diagnosis (AJCC-TNM version 8, CT scan of the chest/abdomen/pelvis within 8 weeks from enrollment, showing no evidence of metastatic disease, Patients must be = 18 years of age, Patients must have a life expectancy greater than 6 months, Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (see Appendix I) and a body weight of > 30kg, Patients must have adequate hematologic reserve, Patients must have an estimated creatinine clearance = 30 ml/min, Patients must have adequate liver function
排除标准
- •Pre-existing medical conditions precluding treatment, Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) = 470 msec in screening ECG or history of familial long QT syndrome, History of interstitial lung disease, Any active disease condition which would render the protocol treatment dangerous or impair the ability of the patient to receive protocol therapy, Any condition that does not permit compliance with the protocol, Live attenuated vaccination administered within 30 days prior to randomization., Any prior carboplatin based therapy, Pregnancy or lactating mothers, Received prior therapy with anti-PD-1, anti-PD-L1,anti-PD-L2, anti- CD137, anti-CTLA-4) antibody, Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease (e.g. colitis or Crohn's disease; not due to radiation reaction), diverticulitis with the exception of diverticulosis, celiac disease (controlled by diet alone) or other serious gastrointestinal chronic conditions associated with diarrhea), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis), rheumatoid arthritis, hypophysitis, uveitis, etc., within the past 3 years prior to the start of treatment, Patients with active or uncontrolled intercurrent illness including, but not limited to: • cardiac dysfunction • active peptic ulcer disease or gastritis • active bleeding diatheses • psychiatric illness • Tuberculosis • HIV virus infection.HIV– infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible; • known active hepatitis B infection • known active hepatitis C infection, History of primary immunodeficiency, history of allogenic organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 28 days of randomization* or a prior history of severe immune mediated toxicity from other immune therapy or grade = 3 infusion reaction, Current or prior use of immunosuppressive medication within 28 days of study entry, Peripheral neuropathy = grade 2, History of allergic or hypersensitivity reactions to any study drug or their excipients
研究者
相似试验
进行中（未招募）
1 期
Trimodality therapy with or without adjuvant Durvalumab to treat patients with bladder cancerMuscle-invasive bladder cancerMedDRA version: 20.1 Level: PT Classification code 10066753 Term: Bladder transitional cell carcinoma stage II System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1 Level: PT Classification code 10066754 Term: Bladder transitional cell carcinoma stage III System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001310-42-ESCanadian Cancer Trials Group (CCTG)238
进行中（未招募）
2 期
A Phase II trial looking at trimodality therapy with or without durvalumab for patients with muscle-invasive bladder cancerMuscle-invasive bladder cancerMalignant neoplasm of bladderCancerISRCTN65058008niversity Hospital Southampton NHS Foundation Trust82
暂停
2 期
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer SubjectsCTRI/2013/06/003778OBI Pharma INC342
进行中（未招募）
不适用
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer SubjectsNeoplasmsKCT0000707Choice Pharma Korea342
进行中（未招募）
1 期
Study of Aztreonam for Inhalation in Children with Cystic Fibrosis and New Infection of the Airways by Pseudomonas aeruginosa bacteriaEUCTR2016-002749-42-FRGilead Sciences, Inc.140